EMAK S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 EUR | -1.64% |
|
+1.89% | -1.64% |
| 03-19 | Bioera tops post-accounts; goes down Restart | AN |
| 03-15 | Giuliano Ferrari buys 20,000 shares in Emak | AN |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 6.71 and 5.68 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.59 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Heavy Machinery & Vehicles
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.64% | 188M | C | ||
| -8.84% | 9.14B | B | ||
| +10.34% | 4.35B | C- | ||
| +2.07% | 4.04B | B | ||
| +27.11% | 2.79B | A- | ||
| +64.52% | 2.27B | - | - | |
| -10.00% | 1.28B | B- | ||
| +18.94% | 834M | C | ||
| +102.98% | 603M | - | - | |
| +39.37% | 546M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EM Stock
- Ratings Emak S.p.A.
